Younger children will now have access to a COVID-19 vaccine — but only if they're considered at higher risk.
The U.S. Food and Drug Administration approved "Spikevax," Moderna's vaccine for children aged 6 months to 11 years old.
The vaccine was previously only available to children through emergency use authorization after approval in Jan. 2022. Approval was expanded to people 12 years and older last year.
RELATED STORY | Doctors and public health organizations sue US health officials over COVID-19 vaccine policy change
The new approval makes the vaccine available to children who are at increased risk for the disease, per the new guidelines set by the FDA in May.
It's expected to be available in the U.S. for the upcoming respiratory virus season that typically begins in fall and winter.
This story was reported on-air by a journalist and has been converted to this platform with the assistance of AI. Our editorial team verifies all reporting on all platforms for fairness and accuracy.
